Navigation Links
First-of-its-kind study shows benefits of electrical stimulation therapy for people paralyzed by spinal cord injury
Date:2/17/2011

Feb. 17, 2011 A new treatment approach which uses tiny bursts of electricity to reawaken paralyzed muscles "significantly" reduced disability and improved grasping in people with incomplete spinal cord injuries, beyond the effects of standard therapy, newly published research shows.

In a study published online in the journal Neurorehabilitation and Neural Repair, Toronto researchers report that functional electrical stimulation (FES) therapy worked better than conventional occupational therapy alone to increase patients' ability to pick up and hold objects.

FES therapy uses low-intensity electrical pulses generated by a pocket-sized electric stimulator.

"This study proves that by stimulating peripheral nerves and muscles, you can actually 'retrain' the brain," says the study's lead author, Dr. Milos R. Popovic, a Senior Scientist at Toronto Rehab and head of the hospital's Neural Engineering and Therapeutics Team. "A few years ago, we did not believe this was possible."

Study participants who received the stimulation therapy also saw big improvements in their independence and ability to perform everyday activities such as dressing and eating, says Dr. Popovic. "This has real implications for people's quality of life and independence, and for their caregivers."

Unlike permanent FES systems, the one designed by Dr. Popovic and colleagues is for short-term treatment. The therapist uses the stimulator to make muscles move in a patient's limb. The idea is that after many repetitions, the nervous system can 'relearn' the motion and eventually activate the muscles on its own, without the device.

The randomized trial, the first of its kind, involved 24 rehabilitation inpatients who could not grasp objects or perform many activities of daily living. All received conventional occupational therapy five days per week for eight weeks. However, one group (9 people) also received an hour of FES therapy daily,
'/>"/>

Contact: Carolyn Lovas
lovas.carolyn@torontorehab.on.ca
416-320-0147
Toronto Rehabilitation Institute
Source:Eurekalert  

Page: 1 2 3

Related biology news :

1. First-of-its-kind map details the height of the globes forests
2. American Sociological Association launches first-of-its-kind teaching tool
3. Designing new molecular tools to study the life and death of a cancer cell
4. Scripps Research study sheds light on RNA on/off switches
5. Study finds massive flux of gas, in addition to liquid oil, at BP well blowout in Gulf
6. Pulmonary fibrosis inhibited by pentraxin-2/SAP in research study
7. NSF funds study of landscape restoration effects on Pennsylvania stream
8. VTT to study one of worlds oldest beers
9. Brandeis study shows economic impact of dengue virus in Americas
10. Field study of smoggy inversions to end
11. Road may disrupt migration, ruin Serengeti, study finds
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
First-of-its-kind study shows benefits of electrical stimulation therapy for people paralyzed by spinal cord injury
(Date:10/29/2014)... in New York City on September 19, 2014, leading ... Society Professor of Genome Sciences and Medicine at the ... of Philosophy of Tel Aviv University, was awarded the ... In addition to her honorary degree from TAU, Prof. ... School of Medicine, and for the past 18 years ...
(Date:10/29/2014)... research potential of the Barcode of Life Data ... Biodiversity Data Journal (BDJ) used ... imported these into a human-readable text developed in manuscript ... were used to study the species distributions of ten ... , BOLD is originally designed to support the generation ...
(Date:10/29/2014)... Cancer Genomics of the Kidney consortium ( CAGEKID ... and exposure to aristolochic acid, an ingredient in ... Nature Communications , have important implications for public ... people every year, and in Central Europe incidence ... the International Cancer Genome Consortium (ICGC), has been ...
Breaking Biology News(10 mins):Geneticist and humanitarian: Prof. Mary-Claire King receives Lasker Award 2Go straight and publish: From Barcode of Life Data Systems to scholarly publishing systems 2Kidney cancer in Central Europe 2
... Jewish Medical and Research Center report in the March ... proteins, known as fibulins 3 and 5, slow the ... vessels from sprouting. The proteins are promising candidates for ... fibulin proteins, which regulate cell proliferation, migration and invasion. ...
... A new UCLA imaging study shows that age-related breakdown ... wiring, correlates strongly with the presence of a key ... are detailed in the January edition of the peer-reviewed ... growing body of evidence that myelin breakdown is a ...
... in the home, but the presence of gas stresses out ... from the University of Nottingham have found that changes in ... warning of leaks in natural gas pipelines. "Our study ... monitor gas leaks via the spectrum of reflected light from ...
Cached Biology News:Proteins stop blood-vessel and tumor growth in mice 2Imaging study links key genetic risk for Alzheimer's disease to myelin breakdown 2Plants used to detect gas leaks, from outer space! 2
(Date:10/27/2014)... (PRWEB) October 27, 2014 Ryan Carfley ... this month to sit down with Bryan Hamilton, the publisher ... Solutions to discuss talent in the Research Triangle region of ... that were highlighted at the roundtable include the role ... the significance of work/life balance and the unique role that ...
(Date:10/27/2014)... 2014 The Italian company ... and sell its artificial "lower limb", after the ...      (Photo: http://photos.prnewswire.com/prnh/20141027/713097 ) ... the definitive judgement has arrived: Roadrunnerfoot, the small ... accessible hi-tech prostheses with composite materials, has won ...
(Date:10/27/2014)... 2014 Kalorama Information says that PCR is ... the United States and is ... researcher said the FDA,s Emergency Use Authorization (EUA) to authorize ... the detection of the Ebola virus was an indication ... assess the IVD industry and its biennial survey on ...
(Date:10/27/2014)... 27, 2014 New Q4-2014 incentives ... , an industry leading unified communication and collaboration ... agents to deliver cloud-based audio and web/video conferencing ... , With SoundConnect’s Q4 incentive partners ... and/or web conferencing licenses sold, now through December ...
Breaking Biology Technology:Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 2Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 3Italian Lower Limb Prosthesis Company Wins Lawsuit Against German Giant Ottobock 2Kalorama: PCR The Go-to Test in Ebola Fight 2Kalorama: PCR The Go-to Test in Ebola Fight 3SoundConnect Unveils Q4 Partner Incentives 2
... as an acceptable primary endpoint, for ... April 28 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: ... reached an agreement with the U.S. Food and Drug ... 3 registration trial of OGX-011, its lead product candidate ...
... containing microneedles has proven just as effective at ... immunization. A team of researchers at Emory University ... new microneedle skin patch method of delivering flu ... people because of decreased pain, increased convenience, lower ...
... of $264.5 million grows 7.8% year-over-year- Operating margin ... Net quarterly book-to-bill ratio equates to 1.25BOSTON, April ... PRXL ) today announced its financial results for ... three months ended March 31, 2009, PAREXEL,s consolidated ...
Cached Biology Technology:OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 2OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 3OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 4OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 5OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 6Flu vaccine given in microneedle skin patches proves effective in mice 2Flu vaccine given in microneedle skin patches proves effective in mice 3PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 2PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 3PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 4PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 5PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 6PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 7PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 8PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 9PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 10PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 11PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 12PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 13PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 14PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 15